Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation (PETMRIinHCC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03839706|
Recruitment Status : Recruiting
First Posted : February 15, 2019
Last Update Posted : September 2, 2020
|Condition or disease||Intervention/treatment||Phase|
|Hepatocellular Carcinoma||Device: PET MRI||Not Applicable|
Hepatocellular Carcinoma (HCC) is the third leading cause of death by cancer worldwide, being responsible for nearly 700,000 deaths in 2012. Liver transplantation (LT) provides the best results as a curative treatment for patients with early-stage HCC. Other curative treatment strategies for early stages HCC include resection and ablation. However, the recurrence rates are higher than LT. Due to organ shortage, better criteria for recipient selection are necessary. The first widely accepted criteria for graft allocation in HCC patients is the so-called Milan Criteria (MC): single HCC nodule ≤ 5 cm or 3 nodules all ≤ 3 cm, achieving a 4-y survival of 85%. Recently, MC is seen as too restrictive, its inclusion preventing patients who might have better survival following LT when compared to other therapies. Reluctant to have sizing-only criteria, the University of Toronto, since 2004, has applied the so-called Extended Toronto Criteria (ETC) to LT, which offers transplant to patients with any size and any number of tumors provide they do not have systemic cancer-related symptoms, extrahepatic disease, vascular invasion or poorly differentiated tumors. A recent prospective study conducted at University Health Network (UHN) has shown 5-years survival rates of 68% when ECT are applied. Recent studies have demonstrated the need to use, besides the lesion size, variables which can predict the biological behavior of the tumor.
Currently, important treatment decisions, like the selection of patients for transplantation, are made on crude, static tumour characteristics such as the size and number of lesions, but do not reflect other aspects of tumour biology. To date, pre-transplantation percutaneous biopsy is the best strategy to assess tumor differentiation and, consequently, tumor biological behavior. However, HCC is a very complex disease. Microscopic and molecular analyses have demonstrated a highly heterogeneous degree of cell differentiation. Patients with more than one tumor may have two or three degrees of cell differentiation between the tumors. Even within a single HCC nodule, more than one clonal mutations can be present. To date, there is not a precise method to determinate the degree of differentiation of each patient's disease and percutaneous core biopsy, an invasive method, is the best estimative the investigators can reach.
Since it is impossible to precisely determine the degree of differentiation of HCC with one single tissue sample, the use of imaging becomes necessary. Magnetic resonance imaging (MRI) and enhanced computed tomography (CT) are extensively validated as staging methods for HCC. The use of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) is still underevaluated in the field of HCC. However, previous studies have demonstrated that 18F-FDG PET/CT may have role in assessing the HCC tumoral differentiation and predict survival after LT. There is no investigation on use of 18F-FDG PET/MRI as a tool to predict biological behavior in HCC.
Recently, the Pugh Lab has developed a circulating tumor DNA (ctDNA) sequencing assay that combines a hybrid-capture method with a novel bioinformatics algorithm to enable full-length sequence analysis of all exons in genes of interest or any other arbitrary genomic region, rather than mutation hotspots13. With the availability of these technologies in our group, the investigators next sought to determine whether these methods were applicable to HCC patients, gathering two innovative tools in transplant patients' care.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Relationship Between 18F-Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging Patterns and Circulating Tumor DNA to Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation (PET MRI in HCC)|
|Actual Study Start Date :||August 22, 2018|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
Experimental: PET MRI Arm
Patient enrolled in the study will have a PET MRI exam scheduled before transplant
Device: PET MRI
18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
- 18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant [ Time Frame: 3 years ]PET scan results will be compared with pathology at the time of transplant. Patients will be followed-up 2 years post transplant for recurrence. PET scan results will be compared for Recurrent/non-recurrent patients.
- 18F-FDG PET/MRI can predict HCC's poor tumoral differentiation [ Time Frame: 3 years ]PET/MRI reports will be compared with pathology at the time of transplant.
- 18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma [ Time Frame: 3 years ]18F-FDG PET/MRI scan results will be compared with levels of ctDNA identified in plasma
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03839706
|Contact: Roxana Bucur||416-370-4800 ext firstname.lastname@example.org|
|Contact: Gonzalo PI Sapisochin, MD||416-340-4800 ext email@example.com|
|Toronto General Hospital||Recruiting|
|Toronto, Ontario, Canada, M5G 2N2|
|Contact: Gonzalo Sapisochin, MD 416-340-4800 ext 3414 firstname.lastname@example.org|